Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations
2023年12月1日 - 1:45AM
ビジネスワイヤ(英語)
- eyonis™ (formerly known as iBiopsy®) scientific poster
presentation: End-to-End AI model for Nodule Detection and
Characterization in Lung Cancer Screening: Performances and
Subpopulation Analysis
- Imaging Lab scientific poster presentation: A CT Imaging
Biomarker for CD8+ Lymphocytes Infiltration Stratification in
Patients with Non-Small Cell Lung Cancer
- Median’s eyonis™ and Imaging Lab teams will attend the event
and be available after poster sessions for presenting the latest
advances of eyonis® AI/ML tech based SaMD and the Imaging Lab
developments.
Regulatory News:
Median Technologies (Paris:ALMDT) announced today that the
Company will be presenting two scientific posters at the 2023 North
America Conference on Lung Cancer (NACLC) being held in Chicago
(Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3.
The NACLC is organized by the International Association for the
Study of Lung Cancer (IASLC), a global multidisciplinary
association dedicated to eradication of all forms of lung
cancers.
The Company will give two poster presentations on December 2nd
from 5:40 to 6:55 pm CT.
Poster PP01.49: End to End AI model for Nodule Detection and
Characterization in Lung Cancer Screening: Performances and
Subpopulation Analysis
Poster PP01.44: A CT Imaging Biomarker for CD8+
Lymphocytes Infiltration Stratification in Patients with Non-Small
Cell Lung Cancer
Median’s eyonis™ and Imaging Lab teams will attend the event and
be available for presenting the latest advances of eyonis® AI/ML
tech based SaMD and the Imaging Lab developments.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and eyonis™
(formerly known as iBiopsy®), our AI/ML tech-based suite of
software as medical devices (SaMD), help biopharmaceutical
companies and clinicians to bring new treatments and diagnose
patients earlier and more accurately. This is how we are helping to
create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130180119/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
過去 株価チャート
から 4 2024 まで 5 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 5 2023 まで 5 2024